Cover Image

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.

A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2-16 years in Asia and Latin America. We analyzed pooled safety data from 18 pha...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sophia Gailhardou (Author), Anna Skipetrova (Author), Gustavo H Dayan (Author), John Jezorwski (Author), Melanie Saville (Author), Diane Van der Vliet (Author), T Anh Wartel (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2016-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A recombinant live attenuated tetravalent vaccine for the prevention of dengue
by: Bruno Guy, et al.
Published: (2017)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
by: Philip K Russell, et al.
Published: (2016)

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
by: Ngoc Huu Tran, et al.
Published: (2019)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
by: Claire Vigne, et al.
Published: (2017)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
by: Fiona R Strouts, et al.
Published: (2016)

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults
by: Susan B. Manoff, et al.
Published: (2019)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
by: Shibadas Biswal, et al.
Published: (2021)

Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
by: Ashish Wasudeo Khobragade, et al.
Published: (2021)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
by: Philippe Moris, et al.
Published: (2019)

Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
by: Scott B. Halstead
Published: (2018)

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
by: Claire Y-H Huang, et al.
Published: (2013)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017)

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil
by: José Cássio de Moraes, et al.
Published: (2022)

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017)

Development and evaluation of a tetravalent botulinum vaccine
by: Dan-Yang Shi, et al.
Published: (2022)

The Occurrence of -nitrosodimethylamine (NDMA) in Swimming Pools: An Overview
by: Saheed Mustapha, et al.
Published: (2021)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
by: Stefan W Metz, et al.
Published: (2018)

Overview of the use of recombinant factor VIIa in children
by: Puetz J
Published: (2014)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
by: Sanjay S. Patel, et al.
Published: (2023)

['Dengue in India: An Overview']
by: Ajay Kumar Prajapati, et al.
Published: (2022)

A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis
by: Julia Tietz, et al.
Published: (2024)

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
by: Sanford R Kimmel
Published: (2008)

Dengue overview: An updated systemic review
by: Muhammad Bilal Khan, et al.
Published: (2023)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
by: Vianney Tricou, et al.
Published: (2023)

The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells
by: Marta Poźniak, et al.
Published: (2021)

Peroxisome Proliferators Attenuate Free Arachidonic Acid Pool in the Kidney Through Inducing Lysophospholipid Acyltransferases
by: Tohru Yamazaki, et al.
Published: (2009)

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
by: Juliana Park, et al.
Published: (2021)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial
by: Shrikant Sharma, et al.
Published: (2018)

ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma
by: Yun Zou, et al.
Published: (2019)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
by: Alemnew F. Dagnew, et al.
Published: (2021)

GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007)

GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007)

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules
by: Eduardo Lazcano-Ponce, et al.
Published: (2018)

SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection
by: Carla Zannella, et al.
Published: (2023)

Overview of Plant-Derived Vaccine Antigens: Dengue Virus
by: Ravindra B Malabadi, et al.
Published: (2011)

The Pool in the Desert
by: Duncan, Sara Jeannette, 1861-1922

The Devil's Pool
by: Sand, George, 1804-1876; Rudaux, Edmond Adolphe, 1840-1908 [Illustrator]; Ives, George Burnham, 1856-1930 [Translator]

The Pools of Silence
by: Stacpoole, H. De Vere (Henry De Vere), 1863-1951